Intranasal Human Abuse Liability (HAL) study to compare the opioid abuse potential after a single dose of hydrocodone extended-release tablet (crushed) versus intranasal hydrocodone powder

Trial Profile

Intranasal Human Abuse Liability (HAL) study to compare the opioid abuse potential after a single dose of hydrocodone extended-release tablet (crushed) versus intranasal hydrocodone powder

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2015

At a glance

  • Drugs Hydrocodone (Primary) ; Hydrocodone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 25 Feb 2015 According to a Teva Pharmaceutical Industries media release, the US FDA has accepted for review an NDA supported in part by results of this study and another study investigating the abuse potential of CEP 33237.
    • 07 Nov 2014 New trial record
    • 08 Oct 2014 Data from this study will support the NDA submission to the US FDA which is expected to be completed by the end of 2014, according to a Teva Pharmaceutical Industries media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top